Stockscreener 앱 받기
7.33
3.81%
-0.29
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Oppenheimer & Co. Inc. Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis announces new publication of research study on NXP900, osimertinib - TipRanks
Nuvectis reports promising cancer treatment results - Investing.com
Nuvectis Pharma Announces a New Publication of a Research - GlobeNewswire
Cleveland Clinic Study Confirms: Nuvectis Drug Makes Standard Lung Cancer Treatment More Effective - StockTitan
Q1 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Price Target Lowered to $11.00 at HC Wainwright - MarketBeat
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst - MarketBeat
FY2028 EPS Estimates for Nuvectis Pharma Reduced by Analyst - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Progress - TipRanks
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets - Marketscreener.com
HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00 - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Updates on Oncology Pipeline - Defense World
Nuvectis Pharma initiated with a Buy at Lucid Capital - TipRanks
Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position - TipRanks
Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright - TipRanks
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year - TipRanks
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights - The Manila Times
How Nuvectis Pharma Cut Losses by $3.3M While Pushing Forward Two Cancer Drug Candidates - StockTitan
Insiders Rewarded With US$915k Addition To Investment As Nuvectis Pharma Stock Hits US$185m - Simply Wall St
Nuvectis Pharma announces pricing of $13.5M public offering - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases $1,200,000.00 in Stock - MarketBeat
Nuvectis pharma investor acquires $1.2 million in stock - MSN
(NVCT) Investment Analysis and Advice - Stock Traders Daily
Nuvectis Pharma Insider Bought Shares Worth $1,200,000, According to a Recent SEC Filing - Marketscreener.com
Major Investment Alert: Shareholder’s Big Move in Nuvectis Pharma! - TipRanks
Nuvectis pharma investor acquires $1.2 million in stock By Investing.com - Investing.com
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis Pharma Closes Stock Offering, Says Underwriter Exercised Overallotment Option - Marketscreener.com
Nuvectis Pharma Announces Closing of $15.5 Million Public - GlobeNewswire
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option - Yahoo Finance
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback - Seeking Alpha
Nuvectis Pharma launches public stock offering - MSN
Nuvectis Pharma 2.7M share Spot Secondary priced at $5.00 - MSN
Nuvectis Pharma Prices $13.5 Million Public Offering of Shares -February 05, 2025 at 10:52 am EST - Marketscreener.com
Nuvectis Pharma Prices of $13.5 Million Public Offering of Common Stock - citybiz
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock - GlobeNewswire
Nuvectis pharma announces proposed public offering of common stock - MSN
Nuvectis Secures Critical $13.5M Funding: Major Push for Revolutionary Cancer Drug Development - StockTitan
Nuvectis Pharma launches public stock offering By Investing.com - Investing.com Australia
Nuvectis Pharma Announces Proposed Public Offering of Common Stock - GlobeNewswire
Nuvectis Pharma's Strategic Funding Move: Key Details on Oncology Pipeline Investment - StockTitan
(NVCT) Trading Signals - Stock Traders Daily
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
2.14%
2.83%
자본화:
|
볼륨(24시간):